title: Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia.
authors.affiliation: Department of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Hossein
authors.initials: H
authors.lastname: Sadrzadeh
authors.forename: Robert
authors.initials: R
authors.lastname: Hasserjian
authors.forename: Amir T
authors.initials: AT
authors.lastname: Fathi
mesh_terms: D059786:Abnormal Karyotype; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D017338:Cladribine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D017809:Fatal Outcome; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000209:etiology / Q000235:genetics / Q000473:pathology*; D011241:Prednisone / Q000008:administration & dosage; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D017338:Cladribine; D014750:Vincristine; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone